No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

Luca Prosperini, Giancarlo Di Battista, Laura Boffa et al.|Journal of Neurology|2018

Cited by 54